期刊文献+

胃肠道间质瘤56例临床特点及诊疗分析 被引量:1

原文传递
导出
摘要 目的探讨胃肠道间质瘤的临床、病理、诊治及预后。方法对56例GIST患者临床资料进行回顾性分析。结果单因素生存分析显示不同部位间质瘤的生存率差异有统计学意义。是否口服格列卫手术切除不全或复发转移间质瘤生存率差异有统计学意义。结论GIST临床表现无特异性。CD117、CD34可协助诊断。以手术为主的综合治疗是可靠的治疗方法。但术后转移复发率高,格列卫治疗术后复发或转移的GIST患者具有较好的临床疗效。
出处 《中国医师杂志》 CAS 2009年第6期800-801,共2页 Journal of Chinese Physician
  • 相关文献

参考文献4

二级参考文献25

  • 1Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach [ J ]. Hum Pathol,2002,33(5 ) :459-465.
  • 2Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors [ J ]. Science, 1998,279(5350) :577-580.
  • 3Rossi CR, Mocellin S, Mencarelli R, et al. Gastrointestinal stromal tumors: from a surgical to a molecular approach [J]. Iht J Cancer,2003,107 (2) :171-176.
  • 4Dematteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stdromal tumors: before and after STI571 [J]. Hum Pathol,2002,33(5) :466-477.
  • 5Joensuu H,Roberts PJ,Sarlomo-Rikala M,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor[J]. N Engl J Med,2001,344(14) :1052-1056.
  • 6van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors:a phase I study[J]. Lancet,2001,358(9291 ) :1421-1423.
  • 7Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J]. N Engl J Med, 2002,347(7) :472-480.
  • 8Blanke C, Joensuu H, Demetri G, et al. Long-term follow up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. Proc Am Soc Clin Oncol Gastrointestinal Cancers Symposium,2004, Abstract 2.
  • 9Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate ( STI571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumors, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase Ⅱ study [ J ]. Eur J Cancer,2003,39 (14) :2006-2011.
  • 10Rankin C, yon Mehren M, Blanke C, et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST-a phase Ⅲ sarcoma group study S0033. Proc Am Soc Clin Oncol,2004 ,Abstract9005.

共引文献16

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部